CYP3A4 and prostate cancer: Since bergamottin is, a known CYP3A inhibitor we used two separate prostate cancer cell lines to test its effect differentially: LNCaP, of Caucasian origin carrying mutant CYP3A5 and expressing low CYP3A5, and MDAPCa2b, of African American origin and carrying one wild type CYP3A5 and expressing higher levels of CYP3A5 active protein.